Shirley D’Sa: What Comes After BTK Inhibitors in Waldenström Macroglobulinaemia?
Shirley D’Sa, Professor of Haematology at United KingdomUnited Kingdom, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Hematology Reports, adding:
”Treatment options following BTK inhibitor failure in Waldenström macroglobulinaemia (WM) remain an important unmet need in our field.
Our recently published article explores the role of bortezomib-based therapy in patients who have progressed following BTKi treatment, providing valuable real-world evidence in an area where prospective data remain limited.
As the therapeutic landscape of WM continues to evolve—with non-covalent BTK inhibitors, BTK degraders, BCL2 inhibitors, bispecific antibodies and cellular therapies all under investigation—it is important not to overlook the potential utility of established agents such as proteasome inhibitors.
The paper contributes to the growing discussion around treatment sequencing in WM and the question many of us increasingly face in clinical practice: what comes after BTKi?
An interesting read for anyone involved in the care of patients with WM and related IgM disorders.”
Title: Bortezomib in Patients Who Fail BTKi in Waldenström Macroglobulinaemia
Authors: Tahanzaib Khwaja, Nicole Japzon, Simona Gatto, Jindriska Lindsay, Charalampia Kyriakou, Shirley D’Sa
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 28, 2026, 03:50ZhiChao (David) Yang: MedicalBench Tests AI in Clinical Reasoning
-
Oct 28, 2026, 03:46Phillip Smith: Strengthening Partnerships and Connections in the Rare Disease and Hemophilia Communities
-
Oct 28, 2026, 03:42Ashley Bradley: Understanding Jalen Hurts’ Diagnosis: DVT and Venous Thromboembolism in Athletes
-
Oct 28, 2026, 03:39Gregory Denomme: Petz and Garratty’s Immune Hemolytic Anemias Third Edition
-
Oct 28, 2026, 03:38Ahmed Alotaibi: Monoclonal Antibodies Challenge Routine Pretransfusion Testing
-
Oct 28, 2026, 03:32Wolfgang Miesbach: Should Prophylaxis in Type 3 VWD Follow the Bleeding Phenotype?
-
Oct 28, 2026, 03:25Owen McCarty: Exploring Platelet Polyphosphates in Coagulation Under Flow
-
Oct 28, 2026, 03:19Arwa Z. Al-Riyami: Key Takeaways from the Blood Conference in Auckland
-
Oct 28, 2026, 03:14Kristopher Jonas: The Ethical Case for Compensated Plasma Donation